Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Adagio Medical Holdings ( (ADGM) ).
On October 10, 2025, Adagio Medical Holdings announced preliminary acute safety and efficacy results from its FULCRUM-VT Study, which evaluates the company’s Ultralow Temperature Cryoablation (ULTC) technology for treating Sustained Monomorphic Ventricular Tachycardia (SMVT). The study, presented at the 20th Annual International Symposium on Ventricular Arrhythmias, showed a 97.4% acute clinical success rate with a favorable safety profile, highlighting the potential of ULTC technology to transform VT treatment. The study involved 207 patients across 19 sites in the U.S. and Canada, with results indicating the system’s promise for a broad patient population, including those with ischemic and non-ischemic cardiomyopathy. The company plans to share further results at the Heart Rhythm 2026 conference, aiming for FDA premarket approval.
The most recent analyst rating on (ADGM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.
Spark’s Take on ADGM Stock
According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.
Adagio Medical Holdings faces significant financial challenges, with consistent losses and negative cash flows being the most impactful factors. While technical indicators suggest some positive momentum, the company’s negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on ADGM stock, click here.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is a medical device company specializing in the development and commercialization of products for treating cardiac arrhythmias. The company utilizes its proprietary Ultra-Low Temperature Cryoablation (ULTC) technology, designed to create large, durable lesions in cardiac tissue. Adagio is currently focused on treating ventricular tachycardia (VT) with its vCLAS™ Cryoablation System, which is CE Marked and under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.
Average Trading Volume: 289,825
Technical Sentiment Signal: Buy
Current Market Cap: $34.61M
For an in-depth examination of ADGM stock, go to TipRanks’ Overview page.